149P Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial

Thymic carcinoma(TC) is the most aggressive subtype of thymic epithelial tumors. According to previous clinical trials, immunotherapy was proved to be effective in second line of treatment. Hence a phase II, prospective clinical trial was conducted by our research team to explore the safety and efficacy of toripalimab (a PD-1 inhibitor) combined with chemotherapy as first line treatment in advanced TC.